Shanghai Kindly Enterprise Development Group (603987) Fair Value & Analysis
Healthcare · CN · Market cap 3.2B CNY
Analysis
Shanghai Kindly Enterprise Development Group (603987) currently trades at ¥7.11, while our model-based Fair Value estimate is ¥12.11 — implying the stock looks roughly 70.3% undervalued today. We read business quality at 83/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Shanghai Kindly Enterprise Development Group Co.,LTD. researches, develops, produces, sales medical devices such as medical puncture needles and medical infusion devices worldwide. It offers syringes, infusion sets, needles, and tube bags. The company also provides including medical packing films, sterilization indicator tapes and needles; and intervention accessories, such as stopcocks. In addition, it offers disposable coaxial biopsy needle, therapy device, disposable pump infusion sets, drug liquid transfer devices, needle-proof prefilled syringe assemblies, polypropylene prefilled injection, disposable water delivery tube, disposable anti-needle injection and pen needle, micro needle, disposable skin-penetrating guide needles and syringes, radiofrequency treatment puncture needle, visual double-lumen endotracheal tube, disposable reflux indwelling needle, root irrigation needle, disposable arterial blood gas needle, compression hemostatic device. Further, it offers puncture care…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.